Late-onset and atypical presentation of Pneumocystis carinii pneumonia in a renal transplant recipient

[1]  P. Terasaki,et al.  Impact of immunosuppression on HLA-antibody formation. , 2006, Clinical transplants.

[2]  H. Furrer,et al.  Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection: a meta-analysis of randomised controlled trials , 2005, BMC infectious diseases.

[3]  M. Yamashita,et al.  Clinical characteristics of Pneumocystis carinii pneumonia in patients with connective tissue diseases , 2005, Modern rheumatology.

[4]  R. Lattes,et al.  Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case–control study , 2003, Transplant infectious disease : an official journal of the Transplantation Society.

[5]  B. Kiberd,et al.  CONVERSION TO RAPAMYCIN IMMUNOSUPPRESSION IN RENAL TRANSPLANT RECIPIENTS: REPORT OF AN INITIAL EXPERIENCE1 , 2000, Transplantation.

[6]  W. Zimmerli,et al.  Pneumocystis carinii pneumonia in human immunodeficiency virus (HIV)-positive and HIV-negative immunocompromised patients. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  B. Julian,et al.  Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. , 1999, Transplantation.

[8]  A. Arroliga,et al.  Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  R. Garland,et al.  Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. , 1998, Chest.

[10]  R. Brunkhorst,et al.  Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. , 1996, Transplantation.

[11]  G. Remuzzi,et al.  A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. , 1996, Transplantation.

[12]  S. Arend,et al.  Pneumocystis carinii Pneumonia in Patients Without AIDS, 1980 Through 1993: An Analysis of 78 Cases , 1995 .

[13]  J. Fishman.  Pneumocystis carinii and parasitic infections in transplantation. , 1995, Infectious disease clinics of North America.

[14]  Sollinger Hw.  Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. , 1995 .

[15]  P Fauchald,et al.  PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION , 1995 .

[16]  European Cooperative Study Group.  Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection , 1995, The Lancet.

[17]  J. Gerrard.  Pneumocystis carinii pneumonia in HIV‐negative immunocompromised adults , 1995, The Medical journal of Australia.

[18]  H. Sollinger.  Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. , 1995, Transplantation.

[19]  K. Sepkowitz.  Pneumocystis carinii pneumonia in patients without AIDS. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  C. Winearls,et al.  Pneumocystis carinii pneumonia in renal transplant recipients--clinical and radiographic features, diagnosis and complications of treatment. , 1985, The Quarterly journal of medicine.

[21]  A. Suffredini,et al.  Pneumocystis carinii pneumonia in renal-transplant recipients treated with cyclosporine and steroids. , 1984, The Journal of infectious diseases.